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1. INTRODUCTION {#med21553-sec-0010}
===============

Toll‐like receptors (TLRs) are integral membrane bound receptors that are vital for innate immunity and help to shape the adaptive immune response. These receptors are triggered by a variety of pathogen‐associated molecular patterns (PAMPs), and danger‐associated molecular patterns (DAMPs). PAMPs are parts of pathogens such as lipoproteins, lipopeptides, and flagella, as well as nucleic acids (either single‐stranded or double‐stranded DNA or RNA),[1](#med21553-bib-0001){ref-type="ref"} while DAMPs are self‐molecules that include multiple heat shock proteins, S100, and high mobility group box 1 (HMGB1) that are released in response to injury or any other anomaly in the cells.[2](#med21553-bib-0002){ref-type="ref"}, [3](#med21553-bib-0003){ref-type="ref"} DAMPs or PAMPs can engage a variety of TLRs; those situated on the cell surface primarily engage TLRs that function on the cell membrane, whereas intracellularly localized TLRs are activated by nucleic acid components, which are made available after pathogen endocytosis or replication. Given their functions, TLRs are considered as the first line in immune defense.[1](#med21553-bib-0001){ref-type="ref"}, [4](#med21553-bib-0004){ref-type="ref"}

The number of functional TLRs can vary in mammals; however, they all have conserved functions, namely the activation of inflammatory mediators. Humans have 10 TLRs; TLR2 (can heterodimerize with TLR1 or TLR6), TLR4, TLR5, and TLR10 are present at the cell membrane, whereas TLR3, TLR7, TLR8, and TLR9 are functionally localized to endosomes (Table [1](#med21553-tbl-0001){ref-type="table"}).[1](#med21553-bib-0001){ref-type="ref"}, [5](#med21553-bib-0005){ref-type="ref"}, [6](#med21553-bib-0006){ref-type="ref"} These receptors invariably work as homodimers or heterodimers, and several studies have suggested that they exhibit unusual dimer characteristics.[7](#med21553-bib-0007){ref-type="ref"}, [8](#med21553-bib-0008){ref-type="ref"} All TLRs form homo‐ and heterodimers, except for TLR3 and TLR5, which are currently considered strictly homodimeric, in the absence of empirical evidence to the contrary.

###### 

Natural and synthetic ligands for TLRs

  TLR          Expression                          PAMPs                                  DAMPs                                                                                         Nature of molecules investigated in clinical trials
  ------------ ----------------------------------- -------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  TLR2 (1/6)   B, Mo, Mac, DCs, Plt N, MyDCs, Mc   Lipoproteins, zymosan, peptidoglycan   HSPs, HMGB1, hyaluronan, HDL (modified)                                                       Lipopeptide, recombinant protein, antibody
  TLR3         DC, B, Plt                          Viral dsRNA                            Self dsRNA                                                                                    Polyinosinic‐polycytidylic acid (polyIC, poly‐ICLC, polyIC12U), anti‐TLR3 antibody
  TLR4         Mo, Mac, N, MyDCs, Mc, B, IE, Plt   Lipopolysaccharide                     HSPs, fibrinogen, heparin sulfate, fibronectin, HA, HMGB1, hyaluronan, oxidized LDL, ANG II   Lipid A derivates (glycolipids), anti‐TLR4 antibody, polysaccharide
  TLR5         Mo, Mac, DC, IE                     Flagellin                              HMGB1                                                                                         Flagella and flagella based molecules
  TLR7         Mo, Mac, pDC, B, Plt                Viral ssRNA                            Self ssRNA                                                                                    SM
  TLR8         Mo, Mac, DC, Mc                     Viral ssRNA                            Self ssRNA                                                                                    SM
  TLR9         Mo, Mac, pDC, B, Plt                Bacterial and viral CpG DNA            Self DNA                                                                                      DNA based, synthetic ssDNA molecules
  TLR10        LN, Mo, S, B, L                     NA                                     NA                                                                                            NA

Abbreviations: ANG II, angiotensin II; B, B cell; DAPM, danger‐associated molecular pattern; DC, dendritic cell; dsRNA, double‐stranded RNA; HA, hyaluronic acid; HDL, high‐density lipoprotein; HMGB1, high mobility group box 1; HSPs, heat shock proteins; IE, intestinal epithelium; L, lung; LC, liver cell; LDL, low‐density lipoprotein; LN, lymph node; Mac, macrophage; Mc, mast cell; Mo, monocyt; MyDC, myeloid dendritic cell; N, neutrophil; NA, not available; PAMP, pathogen‐associated molecular pattern; pDC, plasmacytoid DC; Plt, platelet; S, spleen; SM, small molecule; ssRNA, single‐stranded RNA; TLR, Toll‐like receptor.

John Wiley & Sons, Ltd.

TLRs are composed of three distinct domains, an extracellular domain (ECD) that senses the ligand, a transmembrane domain (TM) that anchors the TLR within membranes, and Toll/interleukin‐1 (IL‐1) receptor (TIR) domain that interacts with other TIR‐containing adapters to initiate signaling (Figure [1](#med21553-fig-0001){ref-type="fig"}A).[9](#med21553-bib-0009){ref-type="ref"}, [10](#med21553-bib-0010){ref-type="ref"}, [11](#med21553-bib-0011){ref-type="ref"} TLRs signaling depends on its dimer assembly, and in the absence of any ligand, TLRs exist either in monomeric forms or weakly dimeric forms that are unable to initiate the signaling. While ligand binding confers dimer stability and induces a conformational change that reorients the TIR domain and initiates signaling.[12](#med21553-bib-0012){ref-type="ref"}, [13](#med21553-bib-0013){ref-type="ref"} TLRs are ideal targets for immune modulation strategies, since they have both known modulators and proven therapeutic potential (Table [1](#med21553-tbl-0001){ref-type="table"}).

![Generalized structure and signaling mechanisms of Toll‐like receptors. A, A typical TLR is composed of three distinct domains, an ECD, a TM domain, and a TIR domain. B, Conventionally, TLRs are divided into two categories; cell surface functional, and endosomally functional TLRs. Endosomal TLRs are mainly activated through nucleic acids, while cell surface--expressed TLRs are activated by a variety of ligands, including proteins and lipoproteins. Upon sensing PAMPs or DAMPs, TLRs dimerize and reorient their TIR domains, allowing the docking of intracellularly localized TIR‐containing proteins, including MAL, MyD88, TRIF, and TRAM. The majority of TLRs convey downstream signals through MyD88; however, TLR3 can signal only through TRIF. Exceptionally, TLR4 can transmit signals through both the MyD88 and TRIF adapter proteins. Therapeutics targeting immune‐related diseases mediated by TLRs are reported to modulate these signaling mechanisms. There are many internal mechanisms that come into action to regulate TLR‐mediated inflammation. These act at all levels starting from cell surface interaction to dent the TLR dimerization, and cytoplasmic interactions to block adapter molecules, alter the posttranslational modification state, and finally in the nucleus to counter overexpression of various interleukins and cytokines. There are many microRNAs that reduce the mRNA stability of different cytokines. All these mechanisms ensure a balanced response toward the invading pathogen or DAMP that unbalance the homeostasis. ABIN3, A20 binding and inhibitor of NFκB‐3; AhR, aryl hydrocarbon receptor; AP1, activated protein 1; ATF3, activating transcription factor 3; Bcl‐3, B‐cell lymphoma 3‐encoded protein; CYLD, cylindromatosis; DOK, downstream of tyrosine kinases; DUSP, dual specificity phosphatases; ECD, extracellular domain; ERK, extracellular‐regulated kinase; IFN, interferon; IkB, inhibitor of κB; IKK, inhibitor of κB kinase; IL, interleukin; IRF, interferon response factor; IRAK‐M, interleukin receptor‐associated kinase M; JNK, c‐Jun N‐terminal kinase; MAL, MyD88 adapter like; MD2, myeloid differentiation factor 2; MIR, microRNA; MKK, mitogen‐activated protein kinase kinase; mRNA, messenger RNA; MyD88, myeloid differentiation primary response 88; MyD88s, myeloid differentiation primary response 88 short; NEMO, NF‐κB essential modulator; NFKBID, NF‐κB inhibitor δ; NF‐κB, nuclear factor κB; Nurr1, nuclear receptor related 1 protein; p38, protein 38; PDLIM2, PDZ and LIM domain 2; PTP1B, protein tyrosine phosphatase‐1B; Reg‐1, regnase‐1; RIPK‐1, receptor interacting protein kinase 1; RP105, radioprotective 105 kDa protein; SARM, sterile α and armadillo‐motif containing protein; SHP‐1, Src homology region 2 domain‐containing phosphatase‐1; SIGGR, single immunoglobulin IL1R‐related molecule; SOCS, suppressor of cytokine signaling; ST2, suppression of tumorigenity 2; ST2L, membrane bound ST2; STAT, signal transducers and activators of transcription; sTLRs, soluble Toll‐like receptor; TAB, TAK‐1‐binding protein; TAK1, transforming growth factor β‐activated kinase 1; TANK, TRAF‐associated NF‐κB activator; TBK1, TANK‐binding kinase 1; TIR, Toll/interleukin‐1 receptor; TLR, Toll‐like receptor; TM, transmembrane domain; TNF‐α, tumor necrosis factor α; TRAF, tumor necrosis factor receptor (TNF‐R)‐associated factor; TRAM, TRIF‐related adapter molecule; TRIF, TIR‐domain‐containing adapter‐inducing interferon‐β; TRIM38, tripartite motif 38; TTP, tristetraprolin; USP4, ubiquitin‐specific protease 4 \[Color figure can be viewed at wileyonlinelibrary.com\]](MED-39-1053-g001){#med21553-fig-0001}

Therefore, it is rational to harness their potential for improving vaccines efficacy, to treat cancers (breast and bladder cancers[14](#med21553-bib-0014){ref-type="ref"}, [15](#med21553-bib-0015){ref-type="ref"}), to inhibit their activity in inflammatory diseases (for instance; rheumatoid arthritis (RA)[16](#med21553-bib-0016){ref-type="ref"} and multiple sclerosis[17](#med21553-bib-0017){ref-type="ref"}), to modulate them in autoimmune diseases such as systemic lupus erythematosus (SLE),[18](#med21553-bib-0018){ref-type="ref"} to fine tune them to generate specific responses (humoral vs cell‐mediated immune responses) and to curb the menopausal osteoporosis.[19](#med21553-bib-0019){ref-type="ref"}, [20](#med21553-bib-0020){ref-type="ref"}, [21](#med21553-bib-0021){ref-type="ref"} Other than these, there are numerous diseases where TLRs play important roles, for that, the interested reviewers are encouraged to consult recent reviews.[22](#med21553-bib-0022){ref-type="ref"}, [23](#med21553-bib-0023){ref-type="ref"}, [24](#med21553-bib-0024){ref-type="ref"} Given their extensive potential benefits, they are the target‐of‐choice for many therapeutic endeavors, and these efforts are bearing fruit, with many compounds that target TLRs are currently at various stages of evaluation in clinical trials.[19](#med21553-bib-0019){ref-type="ref"}

We have therefore revised and gathered relevant data and wish to present it to the scientific community to guide them in their future investigations. The data in this paper has been collected from ongoing clinical trials that either target TLRs or use them to induce improved responses. Data have been organized in a reader‐friendly manner, focusing on the clinical condition, the type of TLR being targeted, the failures and successes of drugs in different phases of clinical trials, and the synergistic efficacy of TLR ligands as adjuvants.

2. TLR SIGNALING {#med21553-sec-0020}
================

In induction of inflammatory responses, TLRs primarily act via the myeloid differentiation response protein 88 (MyD88) and TIR‐domain‐containing adapter‐inducing interferon‐β (TRIF)--mediated pathways.[25](#med21553-bib-0025){ref-type="ref"}, [26](#med21553-bib-0026){ref-type="ref"}, [27](#med21553-bib-0027){ref-type="ref"}, [28](#med21553-bib-0028){ref-type="ref"} On sensing PAMPs or DAMPs, TLRs dimerize and reorient their TIR domains, which allow docking of the TIR containing proteins, MyD88 and MyD88 adapter‐like (MAL). MAL is a bridging adapter frequently involved in TLR4, and to a lesser extent in TLR2, signaling pathways, and it interacts with MyD88 through TIR‐TIR interaction. In addition to the TIR domain, MyD88 contains a death domain that facilitates its interaction with interleukin‐1 receptor (IL1R)‐associated kinase 4 (IRAK4), which can both auto‐phosphorylate and trans‐phosphorylate IRAK2/1.[29](#med21553-bib-0029){ref-type="ref"} This inter‐domain interaction results in a large multimeric molecule, referred to as myddosome, the phosphorylation of which leads to the activation and dimerization of tumor necrosis factor (TNF) receptor--associated factor 6 (TRAF6).[30](#med21553-bib-0030){ref-type="ref"} TRAF6, an E3 ligase that is activated via autoubiquitination in an sequestosome 1 (SQSTM1/p62)‐dependent manner, mediates the ubiquitination of transforming growth factor‐β--activated kinase 1 (TAK1).[31](#med21553-bib-0031){ref-type="ref"}, [32](#med21553-bib-0032){ref-type="ref"} TAK1 belongs to the mitogen‐activated protein kinase kinase kinase (MAPKKK) family and forms a complex with the TAK1 binding proteins, TAB1--3. TAK1 deficiency reduces inflammatory signaling across TLRs; however, no such difference has been observed in response to a deficiency of TAB proteins.[33](#med21553-bib-0033){ref-type="ref"}, [34](#med21553-bib-0034){ref-type="ref"} TAK1/TABs signaling then branches into two arms: activation of nuclear factor κB (NF‐κB) and MAPK. NF‐κB is held inactive in the cytoplasm by inhibitor of κB (IκB), which is phosphorylated by IκB kinase α (IKKα) and IKKβ, and degraded via ubiquitin mediated‐proteasomal degradation, exposing a nuclear localization signal in NF‐κB, and subsequently translocating to the nucleus as reviewed by Kawai and Akira.[35](#med21553-bib-0035){ref-type="ref"} NF‐κB is a hub molecule for inflammatory signals and it induces the expression of a wide array of molecules that cause inflammation, alteration in cell surface receptors, expression of pro‐ and anti‐cancerous molecules, and perturbation in cell motility, among other responses. TAK1 also activates MAPK family members, including MKK7 and/or MKK6/3, resulting in the phosphorylation of p38 and JNK, and culminating in the activation of activated protein 1 (AP1) family transcription factors and messenger RNA (mRNA) stabilization of various genes involved in the regulation of inflammation (Figure [1](#med21553-fig-0001){ref-type="fig"}B).[4](#med21553-bib-0004){ref-type="ref"}, [36](#med21553-bib-0036){ref-type="ref"}

TRIF--dependent signaling is a separate arm of TLR signaling perpetuated only by TLR3 and TLR4, where TRIF interacts with TRAF3 and TRAF6. TRAF6 interacts with receptor interacting protein kinase 1 (RIPK‐1), which transduces the signal by activating TAK1, a crucial branch point in the TLR signaling pathway. TRAF3 activates IKK‐related kinases, such as TANK‐binding kinase 1 (TBK1) and IKKi, along with NEMO, and the transduced signals culminate in interferon (IFN)‐regulatory factor 3 (IRF3) phosphorylation, which translocates into the nucleus after dimerization, inducing expression of type I IFN genes.[4](#med21553-bib-0004){ref-type="ref"}, [36](#med21553-bib-0036){ref-type="ref"} The production of IFNs is the prominent outcome of TLR3 and TLR4 pathways to counter viral infections, which in turn regulated by IRF3. Recently, it has been shown that phosphatidylinositol 5‐phosphate (PtdIns5P) can regulate IRF3 activation. This inositol lipid can bind to and facilitate complex formation between IRF3 and TBK1, leading to the IRF3 phosphorylation by TBK1, situated proximally.[37](#med21553-bib-0037){ref-type="ref"} Furthermore, during viral infection, production of the inositol lipid, PtdIns5P, could be observed by evaluation of PIKfyve activity.[38](#med21553-bib-0038){ref-type="ref"}

3. ENDOGENOUS REGULATION OF TLR SIGNALING {#med21553-sec-0030}
=========================================

Regulation of TLR signaling is achieved through various molecules that restrict it to an appropriate level to avoid any detrimental consequences in the form of autoimmune or inflammatory diseases. These regulatory molecules bind to key components of TLR signaling and quench their activities as reviewed elsewhere.[39](#med21553-bib-0039){ref-type="ref"} The MyD88‐dependent pathway can be suppressed by spleen tyrosine kinase, Cbl‐b, and suppressor of cellular signaling 1 (SOCS1), while the TRIF arm is negatively regulated by sterile α‐ and armadillo‐motif‐containing protein (SARM) and TRAM adapter with Golgi dynamics domain (TAG).[40](#med21553-bib-0040){ref-type="ref"}, [41](#med21553-bib-0041){ref-type="ref"} The inhibition mechanisms of molecules can be unique or may overlap. Similarly, SOCS3 and deubiquitinating enzyme A (DUBA) negatively regulate TRAF3[42](#med21553-bib-0042){ref-type="ref"} while A20, cylindromatosis, TANK, tripartite motif 38 (TRIM38), ubiquitin‐specific protease 4, and small heterodimer partner can negatively influence TRAF6 (Figure [1](#med21553-fig-0001){ref-type="fig"}B).[39](#med21553-bib-0039){ref-type="ref"}, [43](#med21553-bib-0043){ref-type="ref"}, [44](#med21553-bib-0044){ref-type="ref"} TAK1 activation is regulated by A20 and TRIM30α.[45](#med21553-bib-0045){ref-type="ref"} NF‐κB is pivotal in TLR signaling; therefore, it is regulated by numerous molecules, including NF‐κB inhibitor δ (NFKBID), B‐cell lymphoma 3‐encoded protein (BCL‐3), activating transcription factor 3 (ATF3), Nurr1, and PDZ and LIM Domain 2 (PDLIM2).[46](#med21553-bib-0046){ref-type="ref"} IRF3 is an important player in TRIF--dependent pathways that is suppressed by Pin1 and replication and transcription activator‐associated ubiquitin ligase (RAUL).[47](#med21553-bib-0047){ref-type="ref"} Various microRNAs (miRNAs) have been implicated in mRNA level regulation of TLR signaling molecules, including miR‐21, ‐29, ‐126, ‐146a, ‐155, ‐199a, ‐148/152, and ‐466l.[39](#med21553-bib-0039){ref-type="ref"} Moreover, cytokine mRNA stability can also be regulated by regulatory Regnase‐1 and tristetraprolin.[4](#med21553-bib-0004){ref-type="ref"}, [48](#med21553-bib-0048){ref-type="ref"} Collectively, TLR signaling homeostasis is established and maintained by these endogenous modulators (Figure [1](#med21553-fig-0001){ref-type="fig"}B).

4. TLRS AND DISEASES {#med21553-sec-0040}
====================

TLRs are involved in a wide spectrum of diseases that either directly or indirectly exacerbate the conditions. In recent years, many endeavors have been dedicated to delineate this relationship and compile data regarding the TLR involvement in various diseases.[4](#med21553-bib-0004){ref-type="ref"}, [20](#med21553-bib-0020){ref-type="ref"}, [49](#med21553-bib-0049){ref-type="ref"}, [50](#med21553-bib-0050){ref-type="ref"}, [51](#med21553-bib-0051){ref-type="ref"} Here, we would like to present a brief overview of how TLRs influence the pathobiology of inflammatory, autoimmune, and cancerous diseases.[22](#med21553-bib-0022){ref-type="ref"}, [23](#med21553-bib-0023){ref-type="ref"}, [24](#med21553-bib-0024){ref-type="ref"}, [52](#med21553-bib-0052){ref-type="ref"}

Sepsis is the worst outcome of host‐pathogen interaction and is the leading cause of death in United States.[53](#med21553-bib-0053){ref-type="ref"}, [54](#med21553-bib-0054){ref-type="ref"} The infection by Gram‐positive and Gram‐negative bacteria equally contribute to the development of sepsis where exaggerated immune response lead to multiorgan failure and septic shock.[55](#med21553-bib-0055){ref-type="ref"} These bacteria harbor ligands that trigger TLR2 and TLR4; particularly, the presence of LPS significantly contributes into sepsis development. The septic shock is due to the body immune response rather than infection itself.[56](#med21553-bib-0056){ref-type="ref"} For sepsis management, various TLR inhibitors are evaluated clinically, and new modalities are being devised recently.[57](#med21553-bib-0057){ref-type="ref"}

Chronic pulmonary obstructive disease (COPD) is characterized by the poor reversible air flow and bronchial inflammation.[52](#med21553-bib-0052){ref-type="ref"}, [58](#med21553-bib-0058){ref-type="ref"} This condition can also be worsened when TLRs react in response to viral infections. It has been observed that the COPD patients exhibit higher inflammatory cytokines, TNF‐α and CCL5 in infections.[59](#med21553-bib-0059){ref-type="ref"} Among various treatments, the inhibition of TLRs can also be an approach to curb the COPD.[49](#med21553-bib-0049){ref-type="ref"}

The involvement of TLRs in RA, an inflammatory disease, is well known. The exact mechanism of RA initiation is yet debatable; however, it is believed that the PAMPs from commensal flora is crucial for RA initiation.[60](#med21553-bib-0060){ref-type="ref"} After initial insult, an autocrine loop perpetuates that increases matrix metalloproteinases (MMP) and worsen the damage. Moreover, the DNA and peptidoglycan from intestinal bacteria have also been observed in RA joints.[61](#med21553-bib-0061){ref-type="ref"} This result in damaged cells that will release DAMPs such as RNAs, HMGB1, S100‐A8; the presence of such molecules activate TLRs that over‐inflame the situation.

SLE is an autoimmune disease that featured autoantibodies against double‐stranded DNA and nucleic acid‐bound proteins that served both as diagnostic and prognostic markers; however, the initial events are still a mystery.[62](#med21553-bib-0062){ref-type="ref"} SLE patients manifest deficiency in clearing apoptotic cells that promote the formation of the immune complex (IC), and these ICs can trigger the endosomal TLRs. The role of TLR7 (inflammatory) and TLR9 (protective) in SLE can be different due to variation in study samples among different studies; nevertheless, TLR9^−/−^ murine models displayed higher TLR7‐mediated inflammation concluding a regulatory role of TLR9.[63](#med21553-bib-0063){ref-type="ref"}, [64](#med21553-bib-0064){ref-type="ref"}, [65](#med21553-bib-0065){ref-type="ref"}

An autoimmune disease where the immune system destroys the fluid secreting glands, for instance, the salivary gland, has a potential TLR involvement and is known as Sjogren\'s syndrome (SS). The patients with SS exhibit higher TLR expression, with increased expression of inflammatory cytokines in response to TLR7 and TLR9 activation.[66](#med21553-bib-0066){ref-type="ref"}, [67](#med21553-bib-0067){ref-type="ref"}

TLRs participation in cancers act as double‐edge swords; their activation can regress the tumor growth or conversely promote the tumor cells.[20](#med21553-bib-0020){ref-type="ref"}, [67](#med21553-bib-0067){ref-type="ref"} The accumulating data strongly advocate both aspects. Furthermore, it is now well‐acknowledged that the inflammation and cancer are strongly correlated in various diseases.[68](#med21553-bib-0068){ref-type="ref"} Similarly, organs with higher PAMPs density such as gastrointestinal tract and skin are prone to TLR‐mediated oncogenesis along with the organs that expose to indirect TLR agonist such as the liver. The dual role of TLRs in cancers has a significant correlation with the length and amplitude of receptor activation. TLR4 has been reported to promote colon cancer, and its deficiency can alleviate the inflammation as well as tumor burden.[69](#med21553-bib-0069){ref-type="ref"}, [70](#med21553-bib-0070){ref-type="ref"} The liver cancer has also been related to TLR4 activation[71](#med21553-bib-0071){ref-type="ref"}; however, its role may be context dependent in skin cancer.[72](#med21553-bib-0072){ref-type="ref"}, [73](#med21553-bib-0073){ref-type="ref"} Similarly, TLRs are also critical for the cellular transformation in breast cancers, as reviewed before,[14](#med21553-bib-0014){ref-type="ref"} can critically modulate the metabolism in the tumor microenvironment,[74](#med21553-bib-0074){ref-type="ref"} and can regulate other signaling networks to favor pro‐ or anti‐tumor outcomes.[75](#med21553-bib-0075){ref-type="ref"}, [76](#med21553-bib-0076){ref-type="ref"}, [77](#med21553-bib-0077){ref-type="ref"}

5. TLR LIGANDS: ADJUVANTS VS DRUGS {#med21553-sec-0050}
==================================

TLR signaling activates innate immunity and assists in shaping adaptive immunity. Hence, TLR ligands are attractive for use in immunotherapy and are primarily exploited as adjuvants to specifically trigger humoral and/or cell‐mediated responses as reviewed elsewhere.[78](#med21553-bib-0078){ref-type="ref"}, [79](#med21553-bib-0079){ref-type="ref"} They can also magnify the immune response toward certain poorly antigenic targets. Therefore, in the majority of clinical trials, TLR ligands are evaluated as adjuvants.

The number of trials that involve TLR ligands as adjuvants (64%) are double than those considering TLR ligands as drugs (35%). This highlights the immune‐therapy role of TLRs in various diseases and their potential utilization for further exploration for immunomodulation therapy. Additionally, TLR activation can also alter other signaling pathways and it is desirable to cotarget multiple pathways with the aim of achieving improved treatment efficacy. Apart from many ongoing trials, Food and Drug Administration approved TLR ligands, MPLA[80](#med21553-bib-0080){ref-type="ref"} (TLR4 agonist), and imiquimod[81](#med21553-bib-0081){ref-type="ref"} (TLR7 agonist) could be highlighted to address adjuvant or drug roles. MPLA has been used in various vaccine formulations, for instance, Fendrix (Hepatitis B vaccine, GSK), as an adjuvant and imiquimod is famously used to cure viral diseases as a drug.[82](#med21553-bib-0082){ref-type="ref"}, [83](#med21553-bib-0083){ref-type="ref"} The majority of TLRs produce redundant responses (inflammatory vs antiviral); however, there are slight, but distinct, differences in outcomes.[84](#med21553-bib-0084){ref-type="ref"} These differences are largely attributable to the relative roles of ligands and tissue‐dependent TLRs expression.[85](#med21553-bib-0085){ref-type="ref"}, [86](#med21553-bib-0086){ref-type="ref"}

6. THERAPEUTIC INTERVENTIONS TARGETING TLRS {#med21553-sec-0060}
===========================================

Given their vital roles in pathogen clearance, inflammation induction, and cancer pathogenesis, TLRs are attractive targets for manipulation of the immune system in favor of the patients. Therefore, many research centers and pharmaceutical companies are attempting to develop TLRs modulators (Figure [2](#med21553-fig-0002){ref-type="fig"}A). Scaffolds of naturally occurring modulators are ideal candidates for targeting these receptors; thus, these have been heavily investigated in clinical studies and are emerging as a fruitful approach in clinical trials. An exhaustive search of the literature also supports this notion.

![TLRs targeting ligands with respect to their relative clinical trials and disease conditions. A, The total number of clinical trials, activators (including agonists) and inhibitors (including antagonists), and the diversity of ligands are presented. The majority of ligands have been extensively pursued in different diseases, making it difficult to determine their exact numbers. The data indicate that total number of clinical trials exceeds the number of active drugs, suggesting the use of single drugs in multiple clinical trials. B, Clinical trial data showing the current status of drugs targeting TLRs from the disease perspectives. TLR ligands have been evaluated in multiple diseases including cancers, immune disorders, and viral and bacterial diseases. The largest proportion of clinical trials focuses on cancers, followed by immune disorders. "Mixed" indicates those cases where cancer and immune disease have been targeted simultaneously. The category "general" covers vaccination, clinical trials involving healthy volunteers, and those that are not covered by prior instances. This data was gathered from the clinical trials website (clinicaltrials.gov) using various keywords (cancers, immune disorders, TLR, TLRs, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and adjuvant) from June 2017 to Jan 2018. TLR, Toll‐like receptor](MED-39-1053-g002){#med21553-fig-0002}

6.1. TLR2 (TLR1/TLR6) {#med21553-sec-0070}
---------------------

TLR2, in combination with TLR1 or TLR6, detects the lipoproteins, diacyl lipid, or triacyl lipid, respectively, which makes it unique in forming functional heterodimers with other TLRs. Further, TLR2 interacts with modified proteins such as glyco‐ and lipoproteins, peptidoglycan, and zymosan, allowing it to detect a variety of PAMPs.[87](#med21553-bib-0087){ref-type="ref"} This heterogeneity in TLR2 PAMP detection ranges across all types of pathogens, including viruses, bacteria, fungi, and parasites. The TLR2 expression has been detected in immune, endothelial, and epithelial cells,[88](#med21553-bib-0088){ref-type="ref"} indicating that it is a functionally ubiquitous molecule. The homodimerization of TLR2 has been reported; however, further studies are required to confirm these findings.[8](#med21553-bib-0008){ref-type="ref"}, [12](#med21553-bib-0012){ref-type="ref"}, [89](#med21553-bib-0089){ref-type="ref"} The ubiquitous nature and pivotal role of TLR2 make it an attractive drug‐target for various diseases; consequently, many clinical trials have been initiated to evaluate the efficacy of various lipopeptide derivates. Compounds being evaluated in clinical trials include lipopeptides, lipoproteins, oxidized low‐density lipoproteins, and TLR2 specific humanized IgG4 antibody, either alone or in various combinations (Table [2](#med21553-tbl-0002){ref-type="table"}).

###### 

TLR2 (with TLR1 or TLR6) targeting ligands in clinical trials

  Ligand              Phase            Application                                                                                   Target TLR adjuvant/drug   Sponsor/collaborators     NCT number    Type                                     Purpose
  ------------------- ---------------- --------------------------------------------------------------------------------------------- -------------------------- ------------------------- ------------- ---------------------------------------- ---------------------------------------
  CBLB612             Phase 2          Breast cancer                                                                                 TLR2 agonist/drug          Cleveland BioLabs, Inc    NCT02778763   Synthetic lipopeptide                    Neutropenia/recover blood cells count
  SV‐283 (NY‐ESO‐1)   Phase 1          Cancer                                                                                        TLR2 agonist/adjuvant      SapVax LLC                NA            Combination of peptide and SM            Immune stimulation
  ISA‐201             Phase 2          Head and neck tumor                                                                           TLR2/1 agonist/adjuvant    ISA Pharmaceuticals BV    NCT02821494   Combination of peptide and SM, peptide   DC maturation
  OPN‐305‐110         Phases 1 and 2   Second‐line and first line lower risk myelodysplastic syndrome                                TLR2 antagonist/drug       Opsona Therapeutics Ltd   NCT03337451   Monoclonal antibody                      Anti‐inflammation
  OPN‐305             Phase 2          Myelodysplastic syndrome, inflammatory disease, pancreas tumor, kidney transplant rejection   TLR2 antagonist/drug       Opsona Therapeutics Ltd   NCT02363491   Monoclonal antibody                      Anti‐inflammation

Abbreviations: DC, dendritic cells; NA, not available; NCT, national clinical trial; SM, small molecule; TLR, Toll‐like receptor.
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The most recent ligands, such as CBLB612 (synthetic lipopeptide TLR2 agonist), ISA‐201 (peptide agonist for TLR2), OPN‐305 (TLR2 antagonizing IgG4 monoclonal antibody), are in phase 2 in clinical trials primarily for oncogenic therapy, and act both as drugs and as adjuvants (Figure [2](#med21553-fig-0002){ref-type="fig"}B).[90](#med21553-bib-0090){ref-type="ref"}, [91](#med21553-bib-0091){ref-type="ref"} The chemical constituents of these molecules are either lipoprotein or protein derivates, indicating that TLR2 can be targeted using mimetics of its natural ligands. This is not an absolute requirement; however, it is useful to note the existing therapeutic trend while targeting TLR2. Moreover, other than OPN‐305, the majority of molecules in phase 2 trials are agonists of TLR2, highlighting the importance of TLR2 activation in the context of malignancies. Small molecule‐based therapeutics have potential side effects that can be overcome by the application of biologics, including monoclonal antibodies (OPN‐305).[90](#med21553-bib-0090){ref-type="ref"} The inhibition of TLR2 overactivation using OPN‐305 has potential applications in the treatment of inflammatory diseases.

TLR2 in TLR2/1 or TLR2/6 complexes exhibits a cavity on the binding junction of its convex side that allows the docking of Pam3CSK4 and other TLR2‐modulating ligands.[12](#med21553-bib-0012){ref-type="ref"}, [92](#med21553-bib-0092){ref-type="ref"} Pam3CSK4 has two esters and one amide bound lipid chains. The ester chains interact with TLR2, while the amide bound lipid chain can be accommodated into the hydrophobic cavity provided by TLR1 (Figure [3](#med21553-fig-0003){ref-type="fig"}).[12](#med21553-bib-0012){ref-type="ref"}, [93](#med21553-bib-0093){ref-type="ref"} The TLR2/1 complex can further be stabilized by interprotein hydrogen bonding and hydrophobic interactions.[12](#med21553-bib-0012){ref-type="ref"} The hydrophobic cavity in TLR1 has been mutated with bulky amino acids (Met338 and Leu360 to Phe338/360) in TLR6 to make binding of any lipid chain unfavorable, explaining the diacyl requirement for TLR2/6 complex formation.

![TLRs with bound ligands. The ligand binding mechanism of the extracellular TLRs (left, TLR1, 2, 4, 5, 6) and endosomal TLRs (right, TLR3, 7, 8) has been presented. Each monomer has been labeled; however, for the homodimers, the other monomer has been labeled with asterisk (\*). In the case of TLR5, flagellin‐bound single monomer has been given. The respective protein databank (PDB) ID has also been given at the bottom of each structure. TLRs recognize several molecules, including protein, lipopeptide, small molecules and nucleic acids, and the bound ligand with individual TLR has been shown in 2D interaction diagram. The color code for the 2D interaction is given at the bottom of the figure. Black arrows indicate the bound TLR‐ligand. dsRNA, double‐stranded RNA; TLR, Toll‐like receptor; 2D, two‐dimensional \[Color figure can be viewed at wileyonlinelibrary.com\]](MED-39-1053-g003){#med21553-fig-0003}

6.2. TLR3 {#med21553-sec-0080}
---------

TLR3 forms homodimer and signals in an exclusively TRIF--dependent manner in response to viral infections (double‐stranded RNA \[dsRNA\]) and stimulates the production of IFNs. The only known agonist for this TLR is poly‐ICLC (and its derivatives), which is being investigated in various clinical trials.[94](#med21553-bib-0094){ref-type="ref"}, [95](#med21553-bib-0095){ref-type="ref"} The success and ubiquitous nature of poly‐ICLC led to the belief that this was the only realistic possibility for targeting this TLR; however, recent studies have identified other small molecules that can either inhibit or activate TLR3.[96](#med21553-bib-0096){ref-type="ref"}, [97](#med21553-bib-0097){ref-type="ref"} These alternatives will not be available for clinical trials for a considerable period of time. There are a few clinical trials that involve anti‐TLR3 antibody to evaluate its efficacy in healthy individuals and asthmatic patients.[98](#med21553-bib-0098){ref-type="ref"} The success of these proof‐of‐concept studies will lay the foundation of antibody‐based endosomal TLRs targeting in various diseases. However, in rhinoviral infection, the antibody could not demonstrate any improvement in asthmatic condition.[99](#med21553-bib-0099){ref-type="ref"} Targeting of TLR3 is currently used as adjuvant therapy, along with other drugs or vaccines, against a variety of cancers; nonetheless, the sole activation of TLR3 to curb any disease has yet to be successfully explored (Table [3](#med21553-tbl-0003){ref-type="table"}).

###### 

TLR3 targeting ligands in clinical trials

  Ligand                      Phase            Application                                                                                                                                             Target TLR adjuvant/drug   Sponsor/collaborators                                                                                                                                                                             NCT number    Type                                                                   Purpose
  --------------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ---------------------------------------------------------------------- ----------------------------------------
  Poly‐ICLC                   Phases 1 and 2   Low‐grade B‐cell lymphoma                                                                                                                               TLR3 agonist/adjuvant      Joshua Brody, Icahn School of Medicine                                                                                                                                                            NCT01976585   Synthetic dsRNA                                                        DC activation
  Poly‐ICLC (NY‐ESO‐1)        Phases 1 and 2   Melanoma                                                                                                                                                TLR3 agonist/adjuvant      Nina Bhardwaj, Ludwig Institute for Cancer Research, Oncovir Inc, CRI New York City, Icahn School of Medicine                                                                                     NCT01079741   Synthetic dsRNA                                                        Activating humoral and T cell immunity
  Poly‐ICLC                   Phases 1 and 2   Head and neck squamous cell carcinoma, sarcoma, Merkel cell carcinoma, cutaneous T‐cell lymphoma, melanoma, renal‐ bladder‐breast and prostate cancer   TLR3 agonist/adjuvant      Ludwig Institute for Cancer Research, MedImmune LLC, CRI New York City                                                                                                                            NCT02643303   Synthetic dsRNA                                                        Tumor microenvironment modulation
  Poly‐ICLC (Hiltonol)        Unknown          Primary ovarian cancer, fallopian tube cancer, primary peritoneal cancer                                                                                TLR3 agonist/adjuvant      Abramson Cancer Center of the University of Pennsylvania                                                                                                                                          NCT02452775   Synthetic dsRNA, carboxymethylcellulose, poly‐[l]{.smallcaps}‐lysine   Immune stimulation
  Poly‐ICLC (Romidepsin)      Phase 1          Cutaneous T‐cell lymphoma                                                                                                                               TLR3 agonist/adjuvant      New York University School of Medicine, Ludwig Institute for Cancer Research                                                                                                                      NCT02061449   Synthetic dsRNA                                                        Immune stimulation
  Poly‐ICLC (Pembrolizumab)   Phases 1 and 2   Metastatic colon cancer, solid tumor                                                                                                                    TLR3 agonist/adjuvant      Samir N. Khleif, Oncovir Inc, Merck Sharp and Dohme Corp, Augusta University                                                                                                                      NCT02834052   Synthetic dsRNA                                                        Immune stimulation
  Poly‐ICLC                   Phases 1 and 2   Chronic HIV‐1 infection                                                                                                                                 TLR3 agonist/adjuvant      The Campbell Foundation; Oncovir, Inc, National Institutes of Health (NIH), National Institute of Allergy & Infectious Diseases (NIAID), Nina Bhardwaj, Icahn School of Medicine at Mount Sinai   NCT02071095   Synthetic dsRNA                                                        Immune stimulation
  Poly‐ICLC (DCVax‐001)       Phase 1          HIV‐1 infection                                                                                                                                         TLR3 agonist/adjuvant      Rockefeller University                                                                                                                                                                            NCT01127464   Synthetic dsRNA                                                        Immune stimulation
  PRV‐300                     Phase 1          Healthy                                                                                                                                                 TLR3 antagonist/drug       Janssen Research & Development, LLC                                                                                                                                                               NCT02008279   Anti‐TLR3 antibody                                                     Anti‐inflammatory
  PRV‐300                     Phases 1 and 2   Asthma                                                                                                                                                  TLR3 antagonist/drug       Centocor, Inc                                                                                                                                                                                     NCT01195207   Anti‐TLR3 antibody                                                     Anti‐inflammatory

Abbreviations: DC, dendritic cells; dsRNA, double‐stranded RNA; HIV, human immunodeficiency virus; NCT, national clinical trial; TLR, Toll‐like receptor.

John Wiley & Sons, Ltd.

Poly‐ICLC is a synthetic complex of polyinosinic‐polycytidylic acid (nucleic acid mimetics and pathway intermediates), carboxymethylcellulose, and poly‐[l]{.smallcaps}‐lysine (stabilizers). As dsRNA is a natural ligand with relatively low stability, its mimetics could be an affordable means of activating this TLR. Activation of TLR3 depends on dsRNA binding at two opposite sides of its ectodomain, which favorably relocates the C‐terminus of the ECD to facilitate further interactions and increased stabilization.[100](#med21553-bib-0100){ref-type="ref"}, [101](#med21553-bib-0101){ref-type="ref"} TLR3 interacts with the nucleotide backbone, rather than nucleotide bases, which explains its activation via multiple nucleotide combinations (Figure [3](#med21553-fig-0003){ref-type="fig"}).[100](#med21553-bib-0100){ref-type="ref"}

6.3. TLR4 {#med21553-sec-0090}
---------

TLR4 is the only TLR that can function both at the cell membrane and in the endosome, and that can signal through MyD88‐ and TRIF--dependent pathways.[102](#med21553-bib-0102){ref-type="ref"}, [103](#med21553-bib-0103){ref-type="ref"} This has led to the evolution of additional precautions, such as an extensive ligand detection mechanism (cluster of differentiation 14, lipid binding protein, and coreceptor myeloid differentiation factor 2 \[MD2\]) and signal propagation mechanism (requirement of MAL for MyD88 and TRIF‐related adapter molecule \[TRAM\] for TRIF signaling pathways).

Among TLRs, only TLR4 has a suitable ligand binding pocket provided by MD2, rather than by the ectodomain of TLR4. This also provides an additional means of TLR4 (in)activation,[104](#med21553-bib-0104){ref-type="ref"} since MD2 has a large hydrophobic cavity and lipid A derivatives are suitable binding molecules; however, other methods, such as disruption of MD2 binding with TLR4 or inhibition of interaction with the activating ligand, have also been explored.[105](#med21553-bib-0105){ref-type="ref"} In case of MD2 and lipid A interaction, the lipid with six acyl chains (lipid VI‐A) can fully occupy the pocket and reorient the side chain of F126 amino acid into the binding cavity. This creates a favorable environment for the other TLR4/MD2 to dock properly (Figure [3](#med21553-fig-0003){ref-type="fig"}).[106](#med21553-bib-0106){ref-type="ref"} However, in case of a lower number of acyl chains, their binding is unable to reorient the side chain that, in turns, creates a steric hindrance for other heterodimer, leading to TLR4 inhibition.[11](#med21553-bib-0011){ref-type="ref"}, [104](#med21553-bib-0104){ref-type="ref"}, [107](#med21553-bib-0107){ref-type="ref"}

Prominent ligands that activate or inhibit TLR4 include lipid VI‐A and its derivatives (lipid 4A \[antagonist\], monophosphoryl lipid A \[MPLA, a weak agonist\],[108](#med21553-bib-0108){ref-type="ref"} and glucopyranosyl lipid adjuvant \[GLA, an agonist\]),[109](#med21553-bib-0109){ref-type="ref"} and recent studies have also evaluated antibody or peptide‐based drugs.[105](#med21553-bib-0105){ref-type="ref"}, [110](#med21553-bib-0110){ref-type="ref"} Among the TLRs, TLR4 has been extensively evaluated in the highest number of clinical trials and is of interest as a target for treatment of a variety of pathologies including cancers, viral infection, immune diseases, and inflammation. Both the agonistic and antagonistic aspects of TLR4 signaling pathways are being explored (Table [4](#med21553-tbl-0004){ref-type="table"}). In addition to inhibition of MD2‐mediated TLR4 signaling, the interaction of HMGB1 with TLR4 has also been considered in recent trials to improve the efficacy of anticancer drugs (<https://clinicaltrials.gov/ct2/show/NCT02995655>). Besides direct modulation, the addition of a constitutively active form of TLR4 as a vaccine substitute (<https://clinicaltrials.gov/ct2/show/NCT02888756>) and inhibition of dipeptidyl peptidase‐4 (DPP4) that induces IL‐6 expression through TLR4 are also the subjects of therapeutic evaluations.[111](#med21553-bib-0111){ref-type="ref"}

###### 

TLR4 targeting ligands in clinical trials

  Ligand                         Phase            Applications                                                                                            Target TLR adjuvant/drug   Sponsor/collaborators                                                              NCT number    Type                            Purpose
  ------------------------------ ---------------- ------------------------------------------------------------------------------------------------------- -------------------------- ---------------------------------------------------------------------------------- ------------- ------------------------------- ----------------------------------------------------------------------------
  GLA‐SE (MART‐1 antigen)        Phase 1          Stage IIA--IV skin melanoma                                                                             TLR4 agonist/adjuvant      Mayo Clinic, NCI                                                                   NCT02320305   Glycolipid                      Immune stimulation
  LPS                            Phase 1          Asthma                                                                                                  TLR4 agonist/adjuvant      John Sundy, Duke University                                                        NCT00671892   Glycolipid                      Prospective inflammation
  GLA‐SE                         Phase 1          Stage III/IV adult soft tissue sarcoma                                                                  TLR4 agonist/adjuvant      Fred Hutchinson Cancer Research Center, NCI                                        NCT02180698   Glycolipid                      Immune stimulation
  GSK1795091                     Phase 1          Cancer                                                                                                  TLR4 agonist/drug          GSK                                                                                NCT02798978   Glycolipid                      Immune stimulation
  G100                           Phases 1 and 2   Follicular lymphoma (marginal zone allowed during dose escalation only)                                 TLR4 agonist/adjuvant      Immune Design, Merck Sharp & Dohme Corp                                            NCT02501473   Glycolipid                      Tumor microenvironment alteration, DC, T and other immune cells activation
  GLA‐AF, GLA‐SE                 Phase 1          Healthy volunteers                                                                                      TLR4 agonist/adjuvant      Rockefeller University, IDRI Corporation, Immune Design                            NCT01397604   Glycolipid                      Immune stimulation, DC activation
  CCRE                           Phase 1          aHealthy individual                                                                                     TLR4 agonist/adjuvant      University of North Carolina, Chapel Hill, Environmental Protection Agency (EPA)   NCT02847247   LPS                             Inflammation
  Endotoxin                      Phase 1          Endotoxemia                                                                                             TLR4 agonist/adjuvant      Radboud University                                                                 NCT00184990   SM                              Inflammation
  GLA                            Phase 1          Hookworm infection                                                                                      TLR4 agonist/adjuvant      Baylor College of Medicine, George Washington University                           NCT01717950   Glycolipid                      Immune stimulation
  Eritoran                       Phase 2          Insulin sensitivity                                                                                     TLR4 antagonist/drug       The University of Texas Health Science Center at San Antonio                       NCT02321111   Glycolipid                      Lipid‐induced insulin resistance
  NI‐0101                        Phase 2          Rheumatoid arthritis                                                                                    TLR4 inhibitor/drug        NovImmune SA                                                                       NCT03241108   Anti‐TLR4 antibody              TLR4 blocker, anti‐inflammatory
  NI‐0101                        Phase 1          Healthy volunteers                                                                                      TLR4 inhibitor/drug        NovImmune SA                                                                       NCT01808469   Anti‐TLR4 antibody              TLR4 blocker, anti‐inflammatory
  CX‐01                          Phase 1          Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia                                          TLR4 inhibitor/adjuvant    Washington University School of Medicine, Cantex Pharmaceuticals                   NCT02995655   Polysaccharide                  Bone marrow microenvironment disruptor
  Eritoran                       Phase 2          Insulin sensitivity                                                                                     TLR4 antagonist/drug       Nicolas Musi, The University of Texas Health Science Center at San Antonio         NCT02267317   Glycolipid                      Anti‐inflammatory
  MPL (Grass MATA)               Phase 3          Type 1 hypersensitivity                                                                                 TLR4 agonist/adjuvant      Allergy Therapeutics Plc                                                           NCT00414141   Glycolipid                      Anti‐inflammatory
  MPL (Grass MATA)               Phase 2          Allergy                                                                                                 TLR4 agonist/adjuvant      Allergy Therapeutics Plc                                                           NCT02582073   Glycolipid                      Anti‐inflammatory
  GLA‐SE                         Phase 1          Merkel cell carcinoma                                                                                   TLR4 agonist/adjuvant      Immune Design Corp                                                                 NCT02035657   Glycolipid                      Immune stimulation
  GLA (H5 VLP vaccine)           Phase 2          Influenza virus infection                                                                               TLR4 agonist/adjuvant      Medicago Inc                                                                       NCT01991561   Combination of protein and SM   Immune stimulation
  PEPA‐10                        Phase 2          Cancer                                                                                                  TLR4 agonist/adjuvant      Immunovo BV                                                                        NA            SM                              Immune stimulation
  PET‐lipid A (ONT‐10)           Phase 1          Advanced Breast and Ovarian Carcinoma                                                                   TLR4 agonist/adjuvant      Cascadian Therapeutics Inc                                                         NCT02270372   Glycolipid                      Immune stimulation
  PET‐lipid A (ONT‐10)           Phase 1          Solid tumors                                                                                            TLR4 agonist/adjuvant      Cascadian Therapeutics Inc                                                         NCT01556789   Glycolipid                      Immune stimulation
  PET‐lipid A (ONT‐10)           Phase 1          Solid tumors                                                                                            TLR4 agonist/adjuvant      Cascadian Therapeutics Inc                                                         NCT01978964   Glycolipid                      Immune stimulation
  GLA (H7N9 influenza vaccine)   Phase 1          Influenza virus A infection                                                                             TLR4 agonist/adjuvant      Medicago Inc                                                                       NCT02022163   Glycolipid                      Enhance seroprotective antibody titers
  G‐305                          Phase 1          Cancer                                                                                                  TLR4 agonist/adjuvant      Immune Design Corp                                                                 NCT02015416   Combination of protein and SM   Immune stimulation
  Lipid A (SAR‐439794)           Phase 1          Peanut hypersensitivity                                                                                 TLR4 agonist/adjuvant      Sanofi, Immune Design Corp                                                         NCT03463135   Glycolipid                      Immune stimulation
  GLA                            Phase 1          Schistosomiasis                                                                                         TLR4 agonist/adjuvant      Immune Design Corp                                                                 NCT02337855   Glycolipid                      Immune stimulation
  JKB‐121                        Phase 2          Nonalcoholic steatohepatitis                                                                            TLR4 antagonist/drug       TaiwanJ Pharmaceuticals                                                            NCT02442687   SM                              Anti‐inflammatory
  GLA‐SE (CMB‐305)               Phase 2          Sarcoma and its various forms                                                                           TLR4 agonist/adjuvant      Immune Design Corp                                                                 NCT02609984   Glycolipid                      Immune stimulation, DC activation
  GLA‐SE (CMB‐305)               Phase 2          Sarcoma, melanoma, nonsmall‐lung cancer                                                                 TLR4 agonist/adjuvant      Immune Design Corp                                                                 NCT02387125   Glycolipid                      Immune stimulation, DC activation
  JKB‐122                        Phase 2          Chronic hepatitis C                                                                                     TLR4 antagonist/drug       TaiwanJ Pharmaceuticals                                                            NCT02293941   SM                              Anti‐inflammatory
  JKB‐122                        Phase 2          Autoimmune hepatitis, nonalcoholic fatty liver disease                                                  TLR4 antagonist/drug       TaiwanJ Pharmaceuticals                                                            NCT02556372   SM                              Anti‐inflammatory
  Ibudilast (aka MN‐166)         Phase 2          Alcoholism, neuropathic pain, amphetamine and opiate dependence, glioblastoma, traumatic brain injury   TLR4 antagonist/drug       MediciNova Inc                                                                     NCT01860807   SM                              Proinflammatory cytokine suppression
  Intralipid (20%)               NA               Diabetes, obesity                                                                                       TLR4 expression            The University of Texas Health Science Center at San Antonio, NIDDK                NCT01740817   Lipid, SM                       TLR4 expression

Abbreviations: CCRE, clinical center reference endotoxin; GLA, glycopyranosyl lipid A; GSK, GlaxoSmithKline; NA, not applicable; NCI, National Cancer Institute; NCT, national clinical trial; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; SM, small molecule; TLR, Toll‐like receptor.

John Wiley & Sons, Ltd.

6.4. TLR5 {#med21553-sec-0100}
---------

TLR5 detects the bacterial monomeric flagella and mounts an immune response.[112](#med21553-bib-0112){ref-type="ref"}, [113](#med21553-bib-0113){ref-type="ref"} It triggers the MyD88‐dependent pathway in response to enterobacterial invasion and maintains intestinal homeostasis. TLR5 is expressed in almost all cell types with prominent expression in mucosal dendritic cells (DC); however, literature discussing TLR5 is scarce.[114](#med21553-bib-0114){ref-type="ref"}, [115](#med21553-bib-0115){ref-type="ref"} From a therapeutic perspective, all clinical trials targeting TLR5 include use of recombinant flagellin protein.[116](#med21553-bib-0116){ref-type="ref"}, [117](#med21553-bib-0117){ref-type="ref"}, [118](#med21553-bib-0118){ref-type="ref"}, [119](#med21553-bib-0119){ref-type="ref"} Additionally, small molecules to block the TLR5‐flagellin interaction are being tested in preclinical studies.[120](#med21553-bib-0120){ref-type="ref"} In the majority of therapeutic settings, ligands for TLR5 act as adjuvants rather than as stand‐alone drugs, enhancing the efficacy and potency of vaccine candidates (Table [5](#med21553-tbl-0005){ref-type="table"}). TLR5 can be an attractive target because it detects only protein. Short peptides derived from flagellin can be used as activators, while modified forms of such peptides can inhibit TLR5.[118](#med21553-bib-0118){ref-type="ref"}, [121](#med21553-bib-0121){ref-type="ref"} Recently, the crystal structure of zebrafish TLR5 with flagellin was determined, providing insights into its mode of activation (Figure [3](#med21553-fig-0003){ref-type="fig"}).[122](#med21553-bib-0122){ref-type="ref"} The leucine‐rich repeat 9 (LRR9) region in TLR5 has a critical role, and Arg89, Glu114, and Leu93 from flagellin form a hotspot with chemical and geometric complementarity.[122](#med21553-bib-0122){ref-type="ref"} These regions on both proteins should be explored further to design novel therapeutics.

###### 

TLR5 targeting ligands in clinical trials

  Ligand                          Phase            Application                                                              Target TLR adjuvant/drug   Sponsor/collaborators                                       NCT number    Type   Purpose
  ------------------------------- ---------------- ------------------------------------------------------------------------ -------------------------- ----------------------------------------------------------- ------------- ------ --------------------
  Mobilan (M‐VM3)                 Phases 1 and 2   Prostate cancer                                                          TLR5 agonist/adjuvant      Panacela Labs LLC                                           NCT02844699   RP     Immune stimuation
  Mobilan (M‐VM3)                 Phase 1          Prostate cancer                                                          TLR5 agonist/adjuvant      Panacela Labs LLC                                           NCT02654938   RP     Immune stimulation
  Entolimod (aka CBLB502)         Phase 1          Unspecified adult solid tumor                                            TLR5 agonist/adjuvant      Roswell Park Cancer Institute, NCI, Cleveland BioLabs Inc   NCT01527136   RP     Immune stimulation
  VAX125                          Phase 2          Influenza                                                                TLR5 agonist/adjuvant      VaxInnate Corporation                                       NCT00966238   RP     Immune stimulation
  VAX102 (flagellin.HuM2e)        Phase 1          Influenza                                                                TLR5 agonist/adjuvant      VaxInnate Corporation; Bill & Melinda Gates Foundation      NCT00603811   RP     Immune stimulation
  Entolimod (radiation therapy)   Phase 1          Mucositis, various types of squamous cell carcinoma of various tissues   TLR5 agonist/adjuvant      Roswell Park Cancer Institute, NCI, Cleveland BioLabs Inc   NCT01728480   RP     Immune stimulation

Abbreviations: NCI, National Institute of Cancer; NCT, national clinical trial; RP, recombinant protein; TLR, Toll‐like receptor.

John Wiley & Sons, Ltd.

6.5. TLR7/8 {#med21553-sec-0110}
-----------

TLR7 and TLR8 are functionally active in the endosomal compartment, use MyD88 adapter molecules and are activated by single‐stranded RNA (ssRNA).[123](#med21553-bib-0123){ref-type="ref"}, [124](#med21553-bib-0124){ref-type="ref"} Majority of ligands in clinical trials that target TLR7/8 are small molecules (eg, imiquimod \[R837\], resiquimod, or GSK2245035), and most are derivatives of imidazoquinoline, a tricyclic organic molecule.[125](#med21553-bib-0125){ref-type="ref"}, [126](#med21553-bib-0126){ref-type="ref"}, [127](#med21553-bib-0127){ref-type="ref"} (Tables [6](#med21553-tbl-0006){ref-type="table"}, [7](#med21553-tbl-0007){ref-type="table"}, [8](#med21553-tbl-0008){ref-type="table"}). There are functional differences between these two TLRs; for example, plasmacytoid DC and monocytes can be directly activated by TLR7 agonists; however, other than monocytes, TLR8 agonists can directly activate mDCs and monocyte‐derived DCs. TLR7 agonists were more potent when compared with TLR8 agonists regarding antiviral responses in the form of IFN, I‐TAC (IFN‐inducible T‐cell α chemoattractant), and IFN‐regulated cytokines from human peripheral blood mononuclear cells (PBMC).[128](#med21553-bib-0128){ref-type="ref"} Proinflammatory responses, such as expression of IL‐12, TNF‐α, and macrophage inflammatory proteins‐1α (MIP‐1α) were enhanced by TLR8 agonism when compared with TLR7, leading to characteristic differential cell induction profiles.

###### 

TLR7 targeting ligands in clinical trials

  Ligand                               Phase                        Application                                                                                                            Target TLR adjuvant/drug   Sponsor/collaborators                                                                                                                                  NCT number    Type   Purpose/mechanism
  ------------------------------------ ---------------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------- ------ --------------------------------------------------------
  GSK2245035                           Phase 2                      Asthma and rhinitis                                                                                                    TLR7 agonist/drug          GSK, PATH                                                                                                                                              NCT01607372   SM     Type 1 IFN induction
  Imiquimod (R837)                     Phases 1 and 2               Metastatic and recurrent breast cancer                                                                                 TLR7 agonist/adjuvant      New York University School of Medicine, NCI                                                                                                            NCT01421017   SM     Adaptive immune stimulator
  Imiquimod                            Phase 1                      Melanoma and metastatic cancer                                                                                         TLR7 agonist/drug          University of Oklahoma, NCI                                                                                                                            NCT00453050   SM     Immune stimulation
  Imiquimod                            Phase 2                      Breast cancer and breast neoplasms                                                                                     TLR7 agonist/drug          New York University School of Medicine                                                                                                                 NCT00899574   SM     Immune stimulation
  852A                                 Phase 2                      Breast, ovarian, endometrial, and cervical cancer                                                                      TLR7 agonist/drug          Masonic Cancer Center University of Minnesota, Pfizer                                                                                                  NCT00319748   SM     DC activation, IFN‐α secretion
  Imiquimod                            Phase 3                      Influenza viral infection                                                                                              TLR7 agonist/adjuvant      The University of Hong Kong                                                                                                                            NCT02103023   SM     Improve vaccine immunogenicity against influenza virus
  Imiquimod                            Phase 2                      HPV                                                                                                                    TLR7 agonist/drug          Medical University of Vienna                                                                                                                           NCT00941811   SM     Immune stimulation
  Imiquimod (intradermal HBVv)         Phases 2 and 3               Renal failure                                                                                                          TLR7 agonist/adjuvant      The University of Hong Kong                                                                                                                            NCT02621112   SM     Improving vaccine immunogenicity
  Imiquimod (influenza vaccine)        Unknown                      Chronic illness                                                                                                        TLR7 agonist/adjuvant      The University of Hong Kong                                                                                                                            NCT01508884   SM     Activation of APC
  GS‐9620                              Phase 2                      Chronic hepatitis B                                                                                                    TLR7 agonist/adjuvant      Gilead Sciences                                                                                                                                        NCT02166047   SM     Activation of pDC
  Single or multiple GS‐9620           Phase 1                      Hepatitis B                                                                                                            TLR7 agonist/adjuvant      Gilead Sciences                                                                                                                                        NCT01590654   SM     Activation of pDC, Immune stimulation
  Imiquimod                            Unknown                      Photoaged skin and normal skin                                                                                         TLR7 agonist/adjuvant      University of Michigan                                                                                                                                 NCT02889159   SM     Immune stimulation
  RO6864018 (aka ANA773, RO‐6864018)   Phase 1                      Healthy volunteer                                                                                                      TLR7 agonist/drug          Hoffmann‐La Roche                                                                                                                                      NCT02015715   SM     Immunomodulator, Immune stimulation
  RO7020531                            Phase 1                      Chronic Hepatitis B                                                                                                    TLR7 agonist/drug          Hoffmann‐La Roche                                                                                                                                      NCT02956850   SM     Immune stimulation, B and T cell activations
  RO6864018                            Phase 2                      Chronic Hepatitis B                                                                                                    TLR7 agonist/drug          Hoffmann‐La Roche                                                                                                                                      NCT02391805   SM     Immunomodulator, Immune stimulation
  GSK2245035                           Phase 2                      Mild asthma and allergic rhinitis                                                                                      TLR7 agonist/drug          GlaxoSmithKline                                                                                                                                        NCT01788813   SM     Immune stimulation
  GSK2445053                           Phase 1                      Rhinitis, allergic                                                                                                     TLR7 agonist/drug          GlaxoSmithKline                                                                                                                                        NCT01480271   SM     Induction of IFNα
  GSK2245035                           Phase 2                      Allergy rhinitis, asthma, and respiratory tract allergy                                                                TLR7 agonist/drug          GlaxoSmithKline                                                                                                                                        NCT02833974   SM     Immune stimulation
  Imiquimod                            Phase 3                      Actinic keratosis                                                                                                      TLR7 agonist/drug          Graceway Pharmaceuticals, LLC                                                                                                                          NCT00894647   SM     Immune stimulation
  Imiquimod                            Phase 4                      Actinic keratosis                                                                                                      TLR7 agonist/drug          MEDA Pharma GmbH & Co. KG                                                                                                                              NCT00777127   SM     Immune stimulation
  Imiquimod                            Approved (China, Dec 2004)   Keratosis, mycosis fungoides, verruca vulgaris, condyloma, basal cell carcinoma, and molluscum contagiosum infection   TLR7 agonist/adjuvant      Mochida Pharmaceutical Co Ltd, 3 M Pharmaceuticals, Valeant Pharmaceuticals International Inc, iNova Pharmaceuticals Pty Ltd, Intendis GmbH, Meda AB   NCT01453179   SM     Immune stimulation

Abbreviations: GSK, GlaxoSmithKline; HPV, human papilloma virus; IFN, interferon; NCI, National Cancer Institute; NCT, national clinical trial; SM, small molecule; TLR, Toll‐like receptor.

John Wiley & Sons, Ltd.

###### 

TLR3/7/8/9 targeting ligands in clinical trials

  Ligand                         Phase            Application                                                          Target TLR adjuvant/drug       Sponsor/collaborators                                                       NCT number    Type                         Purpose/mechanism
  ------------------------------ ---------------- -------------------------------------------------------------------- ------------------------------ --------------------------------------------------------------------------- ------------- ---------------------------- ------------------------------------------------
  Resiquimod, poly‐ICLC          Phase 2          Glioma, anaplastic astrocytoma, anaplastic astro‐oligodendroglioma   TLR3/7/8 agonist/adjuvant      Jonsson Comprehensive Cancer Center                                         NCT01204684   SM, synthetic dsRNA          Antitumor and antiviral immune stimulation
  Poly‐ICLC, resiquimod (R848)   Phases 1 and 2   Melanoma and its metastatic mucosal variants                         TLR3/7/8 agonist/adjuvant      Craig L Slingluff, Jr, University of Virginia                               NCT02126579   SM, synthetic dsRNA          Antitumor immune stimulation
  Resiquimod (R848)              Phase 1          Influenza vaccination in seniors                                     TLR7/8 agonist/adjuvant        University of British Columbia                                              NCT01737580   SM                           Immune stimulation
  MEDI9197 (durvalumab)          Phase 1          Solid tumors, cutaneous T cell lymphoma                              TLR7/8 agonist/adjuvant        MedImmune LLC                                                               NCT02556463   SM                           Improving antigen presentation
  Resiquimod (NY‐ESO‐1)          Phase 1          Tumors                                                               TLR7/8 agonist/adjuvant        Nina Bhardwaj, CRI New York City, Icahn School of Medicine at Mount Sinai   NCT00821652   SM                           Immune stimulation
  IMO‐8400                       Phases 1 and 2   Waldenstrom\'s macroglobulinemia                                     TLR7/8/9 antagonist/adjuvant   Idera Pharmaceuticals, Inc                                                  NCT02092909   Oligonucleotide antagonist   Immune suppression, TLR7/8/9 signaling blocker
  IMO‐8400                       Phase 2          Plaque psoriasis                                                     TLR7/8/9 antagonist/drug       Idera Pharmaceuticals, Inc                                                  NCT01899729   Oligonucleotide antagonist   Immune suppression
  CPG‐52364                      Phase 1          Healthy volunteers                                                   TLR7/8/9 antagonist/drug       Pfizer                                                                      NCT00547014   SM                           Immune suppression
  IMO‐8400                       Phases 1 and 2   Diffuse large B cell lymphoma                                        TLR7/8/9/ antagonist/drug      Idera Pharmaceuticals, Inc                                                  NCT02252146   Oligonucleotide antagonist   Immune suppression

Abbreviations: CRI, Cancer Research Institute; dsRNA, double‐stranded RNA; NA, not available; NCT, national clinical trial; SLE, systematic lupus erythematosus; SM, small molecule; TLR, Toll‐like receptor.

John Wiley & Sons, Ltd.

###### 

TLR8 targeting ligands in clinical trials

  Ligand                                         Phase            Application                                                                                                                                                    Target TLR adjuvant/drug   Sponsor/collaborators                                                                                 NCT number    Type   Purpose/mechanism
  ---------------------------------------------- ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ----------------------------------------------------------------------------------------------------- ------------- ------ --------------------
  VTX‐2337 (Motolimod)                           Phase 1          A variety and different stages of metastatic squamous neck cancer with occult primary squamous cell carcinoma                                                  TLR8 agonist/adjuvant      University of Washington, NCI                                                                         NCT01334177   SM     Immune stimulation
  VTX‐2337                                       Phase 1          For various types and stages of colorectal, pancreatic, breast, melanoma, non‐small cell lung carcinoma, pancreatic, renal cell carcinoma and solid neoplasm   TLR8 agonist/adjuvant      Mayo Clinic, NCI                                                                                      NCT02650635   SM     Immune stimulation
  VTX‐2337                                       Phase 1          Various types of ovarian cancers and fallopian tube carcinoma, recurrent ovarian carcinoma                                                                     TLR8 agonist/adjuvant      Gynecologic Oncology Group, NCI                                                                       NCT01294293   SM     Immune stimulation
  VTX‐2337                                       Phase 2          Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer                                                                                    TLR8 agonist/adjuvant      VentiRx Pharmaceuticals Inc, Gynecologic Oncology Group                                               NCT01666444   SM     Immune stimulation
  VTX‐2337 (with radiotherapy)                   Phases 1 and 2   Low grade B‐Cell lymphoma                                                                                                                                      TLR8 agonist/adjuvant      VentiRx Pharmaceuticals Inc, Stanford University                                                      NCT01289210   SM     Immune stimulation
  VTX‐2337                                       Phase 2          Carcinoma, squamous cell of head and neck                                                                                                                      TLR8 agonist/adjuvant      VentiRx Pharmaceuticals Inc                                                                           NCT01836029   SM     Immune stimulation
  VTX‐2337 (with anti‐PD‐L1 antibody MEDI4736)   Phases 1 and 2   Ovarian cancer                                                                                                                                                 TLR8 agonist/adjuvant      Ludwig Institute for Cancer Research, MedImmune LLC, VentiRx Pharmaceuticals Inc, CRI New York City   NCT02431559   SM     Immune stimulation

Abbreviations: CRI, Cancer Research Institute; NCI, National Cancer Institute; NCT, national clinical trial; PD‐L1, programmed death‐ligand 1; SM, small molecule; TLR, Toll‐like recptor.

John Wiley & Sons, Ltd.

TLR7 agonists have been actively studied in phase 1 and 2 trials aiming to curb the persistent viral load in HIV‐ and HBV‐infected individuals.[129](#med21553-bib-0129){ref-type="ref"} Moreover, various prodrug (pharmacologically active after metabolism) approaches have also targeted TLR7 (RO6870868 \[single prodrug\] or RO6864018 \[double prodrug\]), and use of these as TLR7 agonists was useful in treating hepatitis B infection in phase 1 clinical trials. The results of this trial were promising and paved the way for phase 2 trials (<https://clinicaltrials.gov/ct2/show/NCT02015715>).

TLR8 can also be activated by ssRNA as natural ligand and by VTX‐2337 (motolimod), a synthetic small molecule selective for TLR8 and is being evaluated in clinical trials.[124](#med21553-bib-0124){ref-type="ref"}, [130](#med21553-bib-0130){ref-type="ref"} TLR8 is a less studied receptor, as its roles overlap with those of TLR7, with which it shares multiple features. When treated with VTX‐2337, TLR8 stimulates TNF‐α and IL‐12 production at lower concentrations in human PBMCs. It also induces TNF‐α and IL‐12 secretion from monocytes and myeloid DCs through the NF‐κB pathway. IFNγ secretion was observed when NK cells were treated with VTX‐2337, which can enhance the lytic capability and antibody‐dependent cell‐mediated cytotoxicity of NK cells.[130](#med21553-bib-0130){ref-type="ref"} VTX‐2337 also improves the efficacy of pegylated liposomal doxorubicin in treatment of ovarian cancer in a mouse model with humanized immune system that has been reconstituted with human CD34^+^ cells.[131](#med21553-bib-0131){ref-type="ref"} This is the only ligand molecule that has been actively evaluated for treatment of a variety of cancers, including head and neck cancer, colorectal, pancreatic, melanoma, breast, renal cell carcinoma, nonsmall--cell lung carcinoma, and other solid neoplasms. In the majority of cases, VTX‐2337 was used in combination with other drugs; however, it is also being evaluated as a stand‐alone drug for treatment of lymphoma.[130](#med21553-bib-0130){ref-type="ref"}

TLR7 and TLR8 share similar activation patterns, both have z‐loops involved in ssRNA recognition, and both possess two binding sites; the first binding site binds guanosine and uridine in TLR7 and TLR8, respectively, while the second binds ssRNA in both cases (Figure [3](#med21553-fig-0003){ref-type="fig"}).[132](#med21553-bib-0132){ref-type="ref"} In TLR7 ssRNA binding primes the receptor for guanosine binding and subsequent dimerization, while synthetic molecules, such as R848, can activate TLR7 without the need for ssRNA.[133](#med21553-bib-0133){ref-type="ref"}, [134](#med21553-bib-0134){ref-type="ref"} Importantly, TLR7 remains monomeric in the absence of any ligand and dimerizes in response to ligand binding; however, its dimer conformation is similar to TLR8 and TLR9. TLR8, on the other hand, is a naturally occurring weak dimer that undergoes conformational change upon ligand binding. The Z‐loop may have an important regulatory role; when it is cleaved from TLR8, TLR8 forms a tight dimer and initiates signaling in the absence of ligand.[135](#med21553-bib-0135){ref-type="ref"}

6.6. TLR9 {#med21553-sec-0120}
---------

TLR9 senses CpG DNA in endosomes and induces the IFN response.[136](#med21553-bib-0136){ref-type="ref"}, [137](#med21553-bib-0137){ref-type="ref"} TLR9 is involved in numerous diseases and has been targeted by various therapeutic approaches. All of the ligands tested in clinical trials that exclusively target TLR9 are either nucleotides or nucleotide derivatives. There are various types of CpG DNAs that are being evaluated in different trials for treatment of diverse conditions. AZD1419 is a C‐type CpG‐based inhaled TLR9 agonist for treatment of asthma and to stimulate IFNs production in lungs. This treatment was classified as well‐tolerated and safe in phase 1 human trials with potential disease‐modifying characteristics and is a promising new therapeutic for use in various immune diseases.[138](#med21553-bib-0138){ref-type="ref"} CYT003 was initially found to be effective; however, its effects were not confirmed in phase 2 clinical trials where 35 patients were treated with varying doses of CYT003.[139](#med21553-bib-0139){ref-type="ref"} Another TLR9 agonist, EMD 1201081, was evaluated in phase 2, open‐label, randomized trial in patients with head and neck cancer, and was found to be ineffective in the tested dose regimen.[140](#med21553-bib-0140){ref-type="ref"} GNKG168 is another CpG‐based molecule that can induce CD8^+^ T cell antitumor cytotoxic responses; however, it was withdrawn in clinical phase 1 because of sponsor reluctance to further support the study[141](#med21553-bib-0141){ref-type="ref"} (NCT01743807) (Tables [7](#med21553-tbl-0007){ref-type="table"} and [9](#med21553-tbl-0009){ref-type="table"}).

###### 

TLR9 targeting ligands in clinical trials

  Ligand                                             Phase            Application                                                                        Target TLR adjuvant/drug   Sponsor/Collaborators                                                                                   NCT Number    Type                                      Purpose/ Mechanism
  -------------------------------------------------- ---------------- ---------------------------------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------- ------------- ----------------------------------------- ------------------------------------
  MGN1703 (Ipilimumab)                               Phase 1          Melanoma                                                                           TLR9 agonist/adjuvant      MD Anderson Cancer Center, Mologen AG                                                                   NCT02668770   DNA‐based molecule                        Antitumor immune stimulation
  SD‐101                                             Phases 1 and 2   Lymphoma and its various forms                                                     TLR9 agonist/adjuvant      Robert Lowsky, NCI, Stanford University                                                                 NCT02254772   CpG‐C class oligodeoxynucleotide          Antitumor immune stimulation
  SD‐101                                             Phases 1 and 2   Grade 1/2/3 follicular lymphoma and recurrent and refractory follicular lymphoma   TLR9 agonist/drug          Robert Lowsky, NCI, Stanford University                                                                 NCT02927964   CpG‐C class oligodeoxynucleotide          Antitumor immune stimulation
  CpG vaccine (autologous tumor cell)                Phase 1          Colorectal neoplasms, anal, colon, and rectal cancers                              TLR9 agonist/adjuvant      Stanford University                                                                                     NCT00780988   Oligonucleotide                           Antitumor immune stimulation
  CYT003                                             Phase 2          Moderate to severe allergic asthma                                                 TLR9 agonist/drug          Cytos Biotechnology AG                                                                                  NCT01673672   Oligonucleotide                           TH1‐mediated immune response
  CYT003‐QbG10                                       Phase 2          Allergic Bronchial Asthma                                                          TLR9 agonist/drug          Cytos Biotechnology AG                                                                                  NCT00890734   Oligonucleotide                           TH1‐mediated immune response
  DUK‐CpG‐001                                        Phase 2          Hodgkin lymphoma, non‐Hodgkin lymphoma                                             TLR9 agonist/adjuvant      David Rizzieri, MD, Duke University                                                                     NCT02115126   Single‐stranded synthetic DNA molecules   Immune stimulation
  MGN1703                                            Phases 1 and 2   HIV                                                                                TLR9 agonist/drug          University of Aarhus                                                                                    NCT02443935   DNA‐based molecule                        Antiviral immune stimulation
  CpG‐7909                                           Phases 1 and 2   Non‐Hodgkin lymphoma, mycosis fungoides                                            TLR9 agonist/adjuvant      Ronald Levy, Lymphoma Research Foundation, American Society of Clinical Oncology, Stanford University   NCT00185965   single‐stranded synthetic DNA molecules   TH1‐like immune stimulator
  CYT003                                             Phase 2          Asthma                                                                             TLR9 agonist/drug          Cytos Biotechnology AG                                                                                  NCT02087644   Oligonucleotide                           TH1‐mediated immune response
  CpG‐7909 (pneumococcal vaccines)                   Phases 1 and 2   HIV infections                                                                     TLR9 agonist/adjuvant      Aarhus University Hospital                                                                              NCT00562939   Oligonucleotide                           Immune stimulator
  GNKG168                                            Phase 1          Relapsed acute lymphoblastic myelogenous leukemia                                  TLR9 agonist/drug          Therapeutic Advances in Childhood Leukemia Consortium                                                   NCT01743807   CpG‐C class oligodeoxynucleotide          Antitumor immune response
  CpG‐7909                                           Phase 1          Malaria                                                                            TLR9 agonist/adjuvant      Oxford University, NIAID                                                                                NCT01351948   Oligonucleotide                           Immune stimulation
  EMD 1201081 (Cetuximab)                            Phase 2          Squamous cell carcinoma of the head and neck                                       TLR9 agonist/adjuvant      EMD Serono                                                                                              NCT01040832   Oligonucleotide                           Immune stimulation
  IMO‐2125                                           Phase 1          Hepatitis C                                                                        TLR9 agonist/drug          Idera Pharmaceuticals, Inc                                                                              NCT00728936   Oligonucleotide                           Immune stimulation
  CpG 10104                                          Phase 1          Hookworm infection                                                                 TLR9 agonist/adjuvant      Baylor College of Medicine, George Washington University                                                NCT02143518   Oligonucleotide                           Immune stimulation
  AZD1419                                            Phase 2          Asthma                                                                             TLR9 agonist/drug          AstraZeneca                                                                                             NCT02898662   C‐type CpG Oligonucleotide                IFN induction
  CpG‐7909 (URLC10‐177, TTK‐567)                     Phases 1 and 2   Esophageal cancer                                                                  TLR9 agonist/adjuvant      Wakayama Medical University, Human Genome Center University of Tokyo                                    NCT00669292   Oligonucleotide                           Immune stimulation
  CpG‐7909                                           Phases 1 and 2   Mycosis fungoides                                                                  TLR9 agonist/adjuvant      Stanford University, NIH                                                                                NCT00226993   Oligonucleotide                           Immune stimulation
  SD‐101                                             Phase 1          Chronic hepatitis C                                                                TLR9 agonist/adjuvant      Dynavax Technologies Corporation, Synteract, Inc, PPD                                                   NCT00823862   CpG‐C class oligodeoxynucleotide          Anti0tumor immune response
  Mycobacterium w.(Mw)‐freeze dried extract 0.5 mL   NA               Optic neuritis                                                                     TLR9 antagonist/adjuvant   Sudhalkar Eye Hospital                                                                                  NCT01424735   Bacterial mix                             Immune suppression
  Hydroxychloroquine sulfate, valsartan              Phase 4          Primary IgA nephropathy                                                            TLR9 inhibitor/adjuvant    Peking Union Medical College Hospital                                                                   NCT02765594   SM                                        Impaired IFN‐α and TNF‐α secretion
  Hydroxychloroquine                                 Phase 3          Sjogren\'s syndrome                                                                TLR9 inhibitor/drug        SNU Hospital                                                                                            NCT01601028   SM                                        Immune suppression
  CpG‐ODN (K3)                                       Phase 1          Lung tumor                                                                         TLR9 agonist/drug          National Institute of Biomedical Innovation, Osaka University                                           NA            Nucleotide based                          Immune stimulation

Abbreviations: IFN, interferon; NA, not applicable; NIAID, National Institute of Allergy & Infectious Diseases; NCI, National Cancer Institute; NCT, national clinical trial; NIH, National Institute of Health; SM, small molecule; SNU, Seoul National University; TLR, Toll‐like receptor; TNF, tumor necrosis factor.

John Wiley & Sons, Ltd.

Similar to other TLRs, TLR9 forms a symmetrical complex with CpG‐DNA; nonetheless, during inhibitory DNA interactions, it remains in a monomeric form. CpG‐DNA binding with TLR9 is symmetric and they form a stoichiometric complex of 2:2, as DNA is recognized by both TLR9 monomers, particularly via the amino‐terminal fragment (LRRNT--LRR10) from one protomer and the carboxy‐terminal fragment (LRR20--LRR22) from the other.[142](#med21553-bib-0142){ref-type="ref"} CpG‐DNA‐based TLR9 inhibition is mediated by binding to the concave surface formed by LRR2--LRR10, thereby inhibiting its signaling.

6.7. TLR10--13 {#med21553-sec-0130}
--------------

Other than TLR1--9, humans also have TLR10 and TLR11, whereas they lack TLR12 and TLR13.[143](#med21553-bib-0143){ref-type="ref"} The expression of TLR10 has been confirmed in humans (spleen, lymph node, B cells, monocytes, and neutrophils)[144](#med21553-bib-0144){ref-type="ref"}; nonetheless, its function and specific ligand are yet to be determined. Recently, it was suggested that TLR10 may act as an anti‐inflammatory TLR, rather than a conventional inflammatory receptor and that it modulates TLR2‐mediated responses through the formation of heterodimers with TLR1 or TLR6.[145](#med21553-bib-0145){ref-type="ref"} Humans have a pseudogene homologous to TLR11 that includes a premature stop codon, resulting in lack of protein expression.[146](#med21553-bib-0146){ref-type="ref"} TLR11 and TLR12 have been studied in mouse and they have shown to detect profilin from *Toxoplasma gondii* and be capable of forming heterodimers.[143](#med21553-bib-0143){ref-type="ref"}

7. INTERDEPENDENT AND CROSS‐TALK AMONG TLR PATHWAYS {#med21553-sec-0140}
===================================================

Since TLRs overlap in their structures and signaling pathways, it is rational to assume that one single ligand can activate multiple TLRs; however, this is less common among plasma membrane expressed TLRs, TLR2/1, TLR2/6, TLR4, and TLR5, and there are a few ligands that can share targets, particularly for TLR2 and TLR4. This situation is very common among endosomal TLRs, partly because they are all involved in sensing nucleic acids, and endosomes have a specific pH range that is also thought to contribute to their activation. Various ligands exert their actions on multiple endosomal TLRs (eg, TLR7/8 or TLR7/8/9), which may imply a combination of multiple pathways in their activity, a common mode of activation, and, to some extent, H^+^ interference of these TLRs being a common factor[147](#med21553-bib-0147){ref-type="ref"}, [148](#med21553-bib-0148){ref-type="ref"} (Tables [7](#med21553-tbl-0007){ref-type="table"} and [10](#med21553-tbl-0010){ref-type="table"}). TLR7 and TLR8 detect ssRNA, which may explain why one ligand is equally effective against both TLRs. Some studies have also explored the independent targeting for either TLR7[149](#med21553-bib-0149){ref-type="ref"} or TLR8.[150](#med21553-bib-0150){ref-type="ref"} The expression patterns of various TLRs differ among tissues, and the extent to which they respond to various ligands may contribute to unexpected results of clinical trials (mostly failure and toxicity issues). TLR2/TLR4 (cell surface) can be regulated by a single ligand, and there are many examples of endosomal TLRs being regulated by single ligands, suggesting that they may have similar sensing and regulatory mechanisms that could be exploited for therapeutic purposes.

###### 

Ligands with either undefined or multiple target TLRs

  Ligand                                                           Phase            Application                                      Mode of action adjuvant/drug     Sponsor/collaborators                                                                                                    NCT number    Type                            Purpose/mechanism
  ---------------------------------------------------------------- ---------------- ------------------------------------------------ -------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------- ------------------------------- --------------------------
  DC‐based vaccine                                                 Phases 1 and 2   Melanoma                                         TLR agonist/adjuvant             Radboud University                                                                                                       NCT01530698   Biologics, SM                   DC activation
  TLR agonist (Tuberculin nasal challenge, timothy grass pollen)   NA               Allergic rhinitis, asthma, latent tuberculosis   TLR agonist/adjuvant             Imperial College London                                                                                                  NCT02090374   Bacterial mix, SM               Immune stimulation
  Mycobacterium w                                                  Phases 2 and 3   Sepsis                                           TLR agonist/adjuvant             Postgraduate Institute of Medical Education & Research, PGIMS, Rohtak, St. John\'s National Academy of Health Sciences   NCT02330432   Bacterial mix                   Immune stimulation
  DRibbles vaccine, imiquimod, HPV vaccine                         Phase 2          Carcinoma, non‐small‐cell lung cancer            TLR2/3/4/7/9 agonists/adjuvant   UbiVac                                                                                                                   NCT01909752   Combination of protein and SM   Immune stimulation
  DRibbles vaccine, imiquimod, HPV vaccine                         Phase 1          Adenocarcinoma of the prostate                   TLR agonist/adjuvant             UbiVac                                                                                                                   NCT02234921   Combination of protein and SM   Immune stimulation
  MB‐11040                                                         Phase 1          Menopause, autoimmune disease, cancer            TLR agonist/drug                 KT & G Life Sciences Corp                                                                                                NA            SM                              Antitumor immunity
  Mycobacterium w                                                  Phases 2 and 3   Severe sepsis, septic shock, immune modulation   TLR agonist/drug                 Postgraduate Institute of Medical Education & Research                                                                   NCT02025660   Bacterial mix                   Immune stimulation
  Insulin                                                          Phase 2          Insulin resistance                               TLR inhibitor/drug               Kaleida Health, American Diabetes Association                                                                            NCT01151605   Biomolecule                     TLR downregulation
  Autologous DC vaccination                                        Phases 1 and 2   Melanoma                                         TLRs agonist/adjuvant            Radboud University                                                                                                       NCT00940004   SM                              DC activation/maturation
  R848 (GP100, MAGE‐3)                                             Phase 2          Melanoma                                         TLR agonist/adjuvant             MD Anderson Cancer Center                                                                                                NCT00960752   SM                              Immune stimulation
  VB‐201                                                           Phase 2          Ulcerative colitis                               TLR2‐4 antagonist/drug           VBL Therapeutics                                                                                                         NCT01839214   SM                              Immune suppression
  PUL‐042                                                          Phase 1          Healthy individuals                              TLR2/6, 9 agonist/adjuvant       Pulmotect Inc                                                                                                            NCT02124278   SM                              Immune stimulation
  PUL‐042                                                          Phase 1          Hematologic diseases, stem cell transplants      TLR2/6, 9 agonist/adjuvant       Pulmotect Inc                                                                                                            NCT03097796   SM                              Immune stimulation

Abbreviations: DC, dendritic cell; HPV, human papilloma virus; NA, not available; NCI, National Cancer Institute; NCT, national clinical trial; PGIMS, Pandit Bhagwat Dayal Sharma; SM, small molecule; TLR, Toll‐like receptor.

John Wiley & Sons, Ltd.

TLRs may antagonize one another under certain physiological conditions. For example, TLR2 and TLR9 antagonize each other in a mouse model for oral infection with *Salmonella enterica*.[151](#med21553-bib-0151){ref-type="ref"} TLR9 deficiency is manifested as reduced survival, exaggerated cytokine responses, and salmonella hepatitis, while TLR2 deficiency produces the opposite effects. Deficiency of either TLR may disrupt NK cell cytotoxicity, and IFN‐γ and ROS production.[151](#med21553-bib-0151){ref-type="ref"}

Synergism is very common in TLRs. When monocyte‐derived DCs have been triggered with a TLR8 ligand, TLR3 or TLR4 are also activated, resulting in expression of IL‐6, IL‐10, IL‐12, and TNF‐α elevation. These results were also confirmed by increased binding of IRF and signal transducers and activators of transcription (STAT) transcription factors to their respective DNA binding sites, which was abolished when NF‐κB, p38, and phosphoinositide 3‐kinase (PI3K) inhibitors were used.[152](#med21553-bib-0152){ref-type="ref"} These data suggest that co‐operation among TLRs is perpetuated, not only at the top level but also among different signaling pathways to ensure proper and balanced expressions of target genes.

Synergy and tolerance of TLRs are long‐established and are critical to the innate immune response. The coadministration of LPS (TLR4 agonist) and MALP‐2 (TLR2 agonist) to mouse macrophages resulted in increased TNF‐α production.[153](#med21553-bib-0153){ref-type="ref"} Repeated treatment with LPS or MALP‐2 resulted in a hyporesponse, also termed tolerance. Intriguingly, pretreatment with any ligand results in lower responses on exposure to the second ligand.[153](#med21553-bib-0153){ref-type="ref"} LPS may cause downregulation of the cell surface expression of TLR4 after the second LPS treatment; however, MALP‐2‐mediated reduction in responses involve modulation of downstream signaling. The acute immune tolerance and cross‐tolerance between TLR4 and TLR9 have been studied,[154](#med21553-bib-0154){ref-type="ref"} indicating that LPS selectively inhibits proinflammatory cytokines, while CpG suppresses both pro‐ and anti‐inflammatory responses. IRAK‐M is critical for the induction of this differential response, and its expression is modulated by IL‐7.[154](#med21553-bib-0154){ref-type="ref"}

The mycobacterium extract,[155](#med21553-bib-0155){ref-type="ref"}, [156](#med21553-bib-0156){ref-type="ref"} and autophagosome‐enriched cancer vaccine (DRibbles),[157](#med21553-bib-0157){ref-type="ref"} which likely contain multiple biological molecules and can trigger numerous TLRs, is being evaluated in clinical trials; however, caution is required when considering the use of such substances in the clinic due to synergy and differential responsiveness of TLRs to various ligands. Moreover, DC vaccines that have been matured using TLR ligands are also therapeutically relevant, owing to the use of TLR ligands in their production.[158](#med21553-bib-0158){ref-type="ref"}, [159](#med21553-bib-0159){ref-type="ref"}

8. FAILED CLINICAL TRIALS {#med21553-sec-0150}
=========================

The proportion of failures of clinical trials depends on the clinical stage, as well as the type of disease; particularly, failure at phase 3 is an impediment to the development of successful therapy for various diseases and TLRs are no exception. For example, eritoran, a TLR4 antagonist, that was being evaluated for treatment of sepsis could not meet its target end‐point in phase 3 when data from \~2000 patients were analyzed.[160](#med21553-bib-0160){ref-type="ref"} Among the reasons of failure of eritoran, there were oversights in study design, patient population differences, improved patient care methods, and mixed bacterial infections.[160](#med21553-bib-0160){ref-type="ref"} Similarly, imiquimod, a TLR7 agonist, produced a divergent result in phase 3 when evaluated for treatment of the skin disorder, molluscum contagiosum (MC) lesions, in children.[161](#med21553-bib-0161){ref-type="ref"} Imiquimod was first approved by the Food and Drug Administration in 1997 for treatment of genital warts. This approval has prejudiced its subsequent off‐label use as the treatment of MC in children, since it was already shown to be effective against viral‐based diseases and its use is supported by several research and clinical investigations.[82](#med21553-bib-0082){ref-type="ref"}, [83](#med21553-bib-0083){ref-type="ref"} This off‐labeled use of imiquimod is still debatable.[83](#med21553-bib-0083){ref-type="ref"}, [161](#med21553-bib-0161){ref-type="ref"} Similarly, in a meta‐analysis, Qin et al ([162](#med21553-bib-0162){ref-type="ref"}) has systematically analyzed the TLR9 agonist effects as observed by other clinical investigations. It has been concluded that the safety profile of TLR9 agonists is acceptable if they are not combine with immunosuppressive drugs.[162](#med21553-bib-0162){ref-type="ref"}

The success rate of transition among different clinical phases (phase 1, 2, 3, and occasionally 4) is highly variable. The likelihood of a molecule passing phase 1 is 63.2%, which is the highest probability for any phase. Phase 2 has the lowest success rate (30.7%), while phase 3 has a success rate of 58.1%.[163](#med21553-bib-0163){ref-type="ref"}, [164](#med21553-bib-0164){ref-type="ref"} Biologics have twice the final success rate (18%), compared with that of small molecules (9%). The transition failure can comprise of drugs that have not met their specific endpoints, and there are cases where particular drugs did not show any improved effect over an existing treatment of a particular condition. The situation is exacerbated when similar molecules are evaluated in multiple interventions, causing an elevated number of failed trials.

Lack of recruitment (23%) and unstated reasons (such as unknown reasons for termination, unable to begin the study, unavailability of a drug, or protocol modification resulting in cessation of a trial; 26%) comprise the majority of reasons for failure of clinical trials targeting TLRs, followed by safety issues (18%) and financial concerns (where a sponsor withdraws the drug; 15%). Moreover, 15% of trials do not show any efficacy in subsequent clinical trials. The inadequate understanding of the biology of TLRs may also contribute to drug failure,[160](#med21553-bib-0160){ref-type="ref"} underlining the need for further studies, increased understanding of the theoretical background of disease etiology and progression, modification of protocols to address problems, and trial redesign.

While many factors contribute to a failed clinical trial, a common reason underlying failure is a lack of serious focus on biomarker discovery and implementation. There is a clear trend of success among those trials including biomarker selection (25.9%) compared with those lacking selection biomarkers (8.4%).[164](#med21553-bib-0164){ref-type="ref"} There are several methods that can be used to reduce failure rates, such as early identification of false drug candidates, stratification of patients, development of diagnostics, proper use of pharmacogenomics through machine learning, and other analysis tools that can provide improvements and efficiencies in patient categorization. Focusing on neglected disease areas can also help to reduce the failure burden. In recent years, the Drugs for Neglected Diseases Initiative has approved six treatments within a decade, with many more in the pipeline. This is not only dramatically reducing the cost of drug development, but also providing hope for individuals affected by neglected diseases and incentivizing the pharmaceutical industry to continue their search for new drugs.

Financial and commercial reasons are also major contributors to trial failures because sponsors are "unwilling," or there are "failure to pursue" investigational drugs for commercially important diseases. This can be reduced if pharmaceutical companies focus on diseases that lack adequate therapeutic intervention, as drugs that show positive effects will soon be marketable. Additionally, if such a trial does fail, it has a lower cost impact on the company.

Drug development is a lengthy process that starts with lead molecule identification and progresses through optimization, animal modeling studies, pharmacokinetic and pharmacodynamic studies, and preclinical and clinical stage trials. Therefore, if a drug fails to show any effect or shows toxicity in clinical studies, there must have been a series of oversights during earlier experimental stages. It is hard to give a single reason for any failure and failures may encompass complex issues, such as the use of subjective, composite, or surrogate endpoints.[165](#med21553-bib-0165){ref-type="ref"} Moreover, biases in outcome reporting and publications; underreporting of adverse events; failure to select an appropriate patient group; preference for relative outcomes, rather than absolute values; no defined core outcome sets; lack of transparency and basic science; inappropriate study population size; and lack of data integrity are among the reasons for trial failures. Finally, during clinical trials involving humans, factors that influence the drug metabolism, distribution, and secretion are diverse that predispose the pharmacokinetically and pharmacodynamically optimized drug molecules to failure.

9. PERSPECTIVES IN TLR TARGETING {#med21553-sec-0160}
================================

Researchers are expending extensive efforts to generate appropriate solutions for various inflammatory, autoimmune, and malignant conditions; however, the process is not straightforward, rather it is littered with unexpected events and outcomes, along with unknown obstructions that severely undermine the efforts of the research community.

In the majority of studies targeting TLRs, the investigated compounds are related to or derived from natural ligands; particularly those targeting TLR3, TLR4, TLR5, and TLR9, and somewhat those for TLR2. TLR7 and TLR8 have the benefit of being targeted by small molecules rather than ssRNA. The instability of ssRNA molecules can hinder their use for TLRs activation. However, since RNAi technology is being evaluated in more than 100 clinical trials,[166](#med21553-bib-0166){ref-type="ref"} stability should not be an issue, rather, tuning of small molecules is far easier than tuning biologics for therapeutic purposes.

Other than molecules derived from natural ligands, it is necessary to focus on the chemical space that can be used to target TLRs.[106](#med21553-bib-0106){ref-type="ref"}, [118](#med21553-bib-0118){ref-type="ref"} This broadening of the chemical space will provide more potent, specific, and less toxic molecules, resulting in fewer trial failures. Biologics are gaining popularity, as they have a higher ratio of success, and are comparatively safe and specific.[167](#med21553-bib-0167){ref-type="ref"}, [168](#med21553-bib-0168){ref-type="ref"}, [169](#med21553-bib-0169){ref-type="ref"}, [170](#med21553-bib-0170){ref-type="ref"}, [171](#med21553-bib-0171){ref-type="ref"} It is estimated that the biologics will soon become the norm in therapeutics, in addition to being responsible for the majority of revenue.[172](#med21553-bib-0172){ref-type="ref"} For different TLRs, the therapeutic trend can vary; however, a rise in antibody‐mediated TLR inhibition (TLR2, TLR3, and TLR4) and novel molecular backbone (independent of PAMPs) have been seen in recent therapeutics.

The evaluation of various drugs for similar or different conditions is also an optimal approach, which can facilitate the development of single drugs for multiple diseases. In this context, research laboratories can screen the outcomes of phase 2 failures that have been abandoned by their sponsors to evaluate them for other symptoms.[173](#med21553-bib-0173){ref-type="ref"} Such an approach can dramatically reduce the cost, speed up the process, and will encourage pharmaceutical companies to share their data with research laboratories for application to other disease targets.

Rather than directly inhibiting TLRs, it may be more appropriate to target the transcription regulation of TLRs to suppress their expression,[174](#med21553-bib-0174){ref-type="ref"} as described in a study where the authors used GST‐21 for cytokine inhibition, which could be reversed by the janus kinase 2 inhibitor, AG490. Since the majority of TLRs regulate the similar pathway, targeting of their downstream inhibitory signaling mechanisms should also be explored to further intensify the benefits of their inhibition.

Lack of clinical data is an impediment to the development of clinical research. It is estimated that approximately half of all clinical trials are not reported in either peer‐reviewed journals or clinical trial websites (clinicaltrials.gov; <http://apps.who.int/trialsearch/>).[175](#med21553-bib-0175){ref-type="ref"}, [176](#med21553-bib-0176){ref-type="ref"}

It is now necessary to develop additional TLR ligands that should not mimic PAMPs, explore new biomarkers for disease progression, revise protocols, and clinical trials, target small subsets of patients, improve the understanding of the basic biology of diseases, and improve final outcomes, which must legitimately refer to the progress of the disease and the effect of the compound being applied.

10. CONCLUSIONS {#med21553-sec-0170}
===============

TLRs are among the ideal targets for exploitation in immunotherapy; however, their biology still needs to be better understood in the context of target diseases. These receptors are capable of inhibiting disease pathophysiology, as well as exacerbating inflammatory diseases. Given this dual role, it is imperative to fine tune their activation using a multidrug approach. Cumulative evidence suggests the participation of TLRs in almost all diseases is unique and can be exploited by including their ligands as adjuvant treatment during regular immunotherapy or as part of other therapeutic regimens.

It is vital to create superior disease models that assist in early phase evaluation of drugs, improve diagnostics and evaluation of disease progression, and facilitate identification of novel biomarkers that reliably indicate disease progression and real‐time disease monitoring. Finally, the availability of clinical trial data should be ensured to guide the scientific community in their endeavors. This would also assist in the refinement of targets and lead molecules and improve the pathophysiological manifestations of diseases. Using a combination of computational power, next‐generation sequencing and proteomic data, machine learning approaches, and improved availability of results, we are hopeful that a dramatic increase in new therapeutic options for various inflammatory diseases and cancers involving TLRs and a decline in clinical trial failures will be achieved.
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